NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast CancerStage II Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage III Breast Cancer

Interventions

DRUG

Anastrozole

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

BIOLOGICAL

Trastuzumab Deruxtecan

Given IV

Trial Locations (9)

32806

WITHDRAWN

Orlando Health, Inc. d/b/a Orlando Health UF Health Center, Orlando

46804

WITHDRAWN

Ft. Wayne Medical Oncology and Hematology, Inc., Fort Wayne

67214

RECRUITING

Cancer Center of Kansas, Wichita

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

90602

RECRUITING

Torrance Memorial Physician Network / Cancer Care, Torrance

RECRUITING

PIH Health, Whittier

90720

RECRUITING

Cancer Blood and Specialty Clinic, Los Alamitos

92835

RECRUITING

St. Joseph Heritage Healthcare, Fullerton

02114

RECRUITING

Massachusetts General Hospital, Boston